EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3

Norhan B B Mohammed, Rajib K Shil, Charles J Dimitroff iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26104882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Norhan B B Mohammed und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY 10016, USA. Hauptthemen laut MEDLINE: Galectin 3, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIU Dissertation Year Fellowship, Sigma Xi GIAR, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic melanoma is an aggressive skin cancer with a five-year survival rate of only 35%. Despite recent advances in immunotherapy, there is still an urgent need for the development of innovative therapeutic approaches to improve clinical outcomes of patients with metastatic melanoma. Prior research from our laboratory revealed that loss of the I-branching enzyme β1,6 N-acetylglucosaminyltransferase 2 (GCNT2), with consequent substitution of melanoma surface I-branched poly-N-acetyllactosamines (poly-LacNAcs) with i-linear poly-LacNAcs, is implicated in driving melanoma metastasis. In the current study, we explored the role of galectin-3 (Gal-3), a lectin that avidly binds surface poly-LacNAcs, in dictating melanoma aggressive behavior. Our results show that Gal-3 favors binding to i-linear poly-LacNAcs, while enforced GCNT2/I-branching disrupts this interaction, thereby suppressing Gal-3-dependent malignant characteristics, including extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway activation, BCL2 expression, cell proliferation, and migration. This report establishes the crucial role of extracellular Gal-3 interactions with i-linear glycans in promoting melanoma cell aggressiveness, placing GCNT2 as a tumor suppressor protein and suggesting both extracellular Gal-3 and i-linear glycans as potential therapeutic targets for metastatic melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 3MelanomaSkin NeoplasmsHumansCell Line, TumorN-AcetylglucosaminyltransferasesPolysaccharidesCell ProliferationCell MovementMAP Kinase Signaling SystemBlood ProteinsGalectins

Stichwörter der Autor:innen

GCNT2Galectin-3glycansmelanomametastasis

Substanzen

Galectin 3N-AcetylglucosaminyltransferasesLGALS3 protein, humanPolysaccharidespoly-N-acetyllactosamineBlood ProteinsGalectins

Autor:innen und Institutionen

  • The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY 10016, USA.
  • Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.

ORCID-Profile: Charles J Dimitroff

Förderung

  • FIU Dissertation Year Fellowship
  • Sigma Xi GIAR
  • NCI NIH HHS
  • FIU Presidential Fellowship
  • NIH HHS
  • NIH/NCI

Zitieren

APA

Mohammed, N. B. B., Shil, R. K., & Dimitroff, C. J. (2025). Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104882

Vancouver

Mohammed NBB, Shil RK, Dimitroff CJ. Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104882

BibTeX
@article{Mohammed2025,
  author = {Mohammed, Norhan B B and Shil, Rajib K and Dimitroff, Charles J},
  title = {Melanoma Glycome Regulates the Pro-Oncogenic Properties of Extracellular Galectin-3},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26104882}
}
Kostenlos starten →